ORIGINAL ARTICLE
Evaluation of CXCL12 and CXCR4 to predict poor survival in lymph node-positive colorectal cancer patients
1
Kırıkkale University Faculty of Medicine, Department of Pathology, Kırıkkale, Turkey
2
Istanbul Education and Research Hospital, Department of Pathology, Istanbul, Turkey
3
Acıbadem University Faculty of Medicine, Department of Pathology, Istanbul, Turkey
4
Bağcılar Training and Research Hospital, Department of Pathology, Istanbul, Turkey
5
Tekirdağ University Faculty of Medicine, Department of General Surgery, Istanbul, Turkey
Submission date: 2020-05-11
Final revision date: 2020-10-14
Acceptance date: 2020-11-15
Publication date: 2021-02-22
Pol J Pathol 2020;71(4):328-338
KEYWORDS
TOPICS
ABSTRACT
It is well known that interactions in the tumour microenvironment are very important in the progression of tumours. We investigated the relationship between chemokine ligand type 12 (CXCL12), chemokine receptor type 4 (CXCR4) and survival in advanced colorectal cancers (CRC). Primary tumour samples of stage III-IV CRC patients were investigated for CXCL12 and CXCR4. Chemokine ligand type 12 and CXCR4 expressions were significantly associated with poor prognostic factors (e.g. for CXCL12: lymphatic invasion [p = 0.009], positive surgical margin [p = 0.006], advanced stage [p = 0.028], etc.). Also, these parameters were independent risk factors for low LIR (e.g. for CXCL12: Odds ratio [OR] = 2.27, p = 0.001) and low tumour stroma-ratio (TSR; e.g. for CXCL12: OR = 1.18, p = 0.003). In univariate analysis, 5-year RFS and OS were poor (e.g. for CXCL12: RFS, p < 0.001 and OS, p = 0.001). Multivariate analysis showed that these parameters were independent poor survival parameters for RFS and OS (e.g. for CXCL12: Hazard ratio [HR] = 3.54 [CI: 1.52-4.67], p = 0.001 and HR = 2.74 [1.48-4.71], p = 0.025). We showed that CXCL12 and CXCR4 expressions are poor prognostic factors in lymph node-positive CRC patients and are associated with low TSR and low LIR.
REFERENCES (44)
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34.
2.
Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet 2019; 394: 1467-1480.
4.
Valdivieso L, et al. New trends in the therapeutic approach to metastatic colorectal cancer. Int J Med Sci 2018; 15: 659-665.
5.
Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl. 3):.
7.
Guo F, Wang Y, Liu J, et al. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene 2016; 35: 816-826.
8.
Sun X, Cheng G, Hao M, et al. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metast Rev 2010; 29: 709-722.
9.
Hu TH, Yao Y, Yu S, et al. SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/beta-catenin signaling pathway. Cancer Lett 2014; 354: 417-426.
10.
Liu F, Lang R, Wei J, et al. Increased expression of SDF-1/CXCR4 is associated with lymph node metastasis of invasive micropapillary carcinoma of the breast. Histopathology 2009; 54: 741-750.
11.
Xie S, Zeng W, Fan G, et al. Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis. Anticancer Res 2009; 29: 4751-4758.
12.
Liang JJ, Zhu S, Bruggeman R, et al. High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarker Prev 2010; 19: 2598-2604.
13.
Jiang Y, Wu X, Shi B, et al. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol 2006; 103: 226-233.
14.
Dong P. Effect of CXCL12/CXCR4 on increasing the metastatic potential of non-small cell lung cancer in vitro is inhibited through the downregulation of CXCR4 chemokine receptor expression. Oncol Lett 2014; 7: 941-947.
15.
Tan CT, Chu CY, Lu YC, et al. CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. Carcinogenesis 2008; 29: 1519-1527.
17.
(SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 2011; 17: 2074.
18.
Quail DF, Joyce JA. Microenvironmental regulation of tumour progression and metastasis. Nat Med 2013; 19: 1423-1437.
19.
Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumour stroma. Exp Cell Res 2010; 316: 1324-1331.
20.
Park JH, Richards CH, McMillan DC. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol 2014; 25: 644-651.
21.
Dupre A, Malik HZ. Inflammation and cancer: What a surgical oncologist should know. Eur J Surg Oncol 2018; 44: 566-570.
22.
Galon J, Pages F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10: 205.
23.
Mei Z, Liu Y, Liu C, et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer 2014; 110: 1595-1605.
25.
recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387-391.
26.
Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer 2010; 116: 5336-5339.
27.
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259-271.
28.
Zengin M. Tumour budding and tumour stroma ratio are reliable predictors for death and recurrence in elderly stage I colon cancer patients. Pathol Res Pract 2019; 215: 152635.
29.
McGraw KO. Forming inferences about some intraclass correlation coefficient. Psychol Methods 1996; 1: 30-46.
30.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
31.
Le Y, Zhou Y, Iribarren P. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 2004; 1: 95-104.
32.
Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203: 2201-2213.
33.
Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumour cells and their microenvironment. Blood 2006; 107: 1761-1767.
34.
Cao Y, Chen C, Weatherbee JA, et al. gro-β, a CXC chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice. J Exp Med 1995; 182: 2069-2077.
35.
Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 1999; 154: 1125-1135.
36.
Tachibana K, Hirota S, Lizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393: 591-594.
38.
Hassan S, Buchanan M, Kahan J, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 2011; 129: 225-232.
39.
Conley-LaComb MK, Semaan L, Singareddy R, et al. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis. Mol Cancer 2016; 15: 68.
40.
Kim J, Mori T, Chen SL, et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 2006; 244: 113-120.
41.
Gil M, Seshadri M, Komorowski MP, et al. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A 2013; 110: E1291-300.
42.
Zengin M. Prognostic role of tumor-infiltrating T lymphocytes in stage IIA (T3N0) colon cancer: A broad methodological study in a fairly homogeneous population. Ann Diagn Pathol 2019; 41: 69-78.
43.
Mesker WE, van Pelt GW, Tollenaar RAEM. Tumor stroma as contributing factor in the lymph node metastases process? Oncotarget 2019; 10: 922-923.
44.
Smit M, van Pelt G, Roodvoets A, et al. Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study. JMIR Res Protoc 2019; 8: 13464.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
